share_log

Roth MKM Maintains Buy on Revelation Biosciences, Raises Price Target to $15

Benzinga Real-time News ·  Feb 14, 2023 09:37

Roth MKM analyst Jonathan Aschoff maintains Revelation Biosciences (NASDAQ:REVB) with a Buy and raises the price target from $5 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment